Inclusion Criteria:

          1. Subject is capable of understanding the purpose and risks of the study and has
             provided written Informed Consent.

          2. Subject is male or female, aged at least 18 years.

          3. Subject has a histologically or cytologically confirmed diagnosis of an advanced
             malignant solid tumor(s) who have received all conventional therapies considered
             appropriate by Investigator and have a tumor that is easily accessible for treatment.

          4. Subject's Eastern Cooperative Group (ECOG) performance status is 0-2 at Screening.

          5. Subject has acceptable liver function at Screening, as evidenced by:

               1. Bilirubin < 1.5 x ULN (upper limit of normal)

               2. AST (SGOT) and ALT (SGPT) < 3.0 x ULN (upper limit of normal)

               3. Alkaline Phosphatase < 2.5 x ULN (upper limit of normal)

          6. Subject has a Serum Creatinine < 1.5 x ULN (upper limit of normal)

          7. Subject has acceptable hematologic status at Screening, as evidenced by:

               1. Absolute neutrophil count > 1,500 cells/mm3; > 1.5 x 109/L, and

               2. Platelet count > 75,000/mm3; > 75.0 x 109/L, and

               3. Hemoglobin (HGB) > 10.0 g/dL; > 6.2 mmol/L

          8. Subject has an INR < 1.5

          9. If subject has archival tissue formalin-fixed paraffin-embedded block(s) or previously
             cut archival tissue, submit 1 H&E slide and 5 unstained slides.

         10. Female subjects of childbearing potential (i.e., women who have not been surgically
             sterilized or have not been post-menopausal for at least one year), and male subjects
             with partners of childbearing potential, must agree to use medically acceptable
             methods of contraception beginning on Study Day 1 and continuing until at least four
             weeks after administration of the subject's final dose of AdAPT-001. Medically
             acceptable contraception is defined as either: 1) usage by at least one of the
             partners of a barrier method of contraception, together with usage by the female
             partner, commencing at least three months prior to Study Day 1, of a stable regimen of
             any form of hormonal contraception or an intra-uterine device, or 2) usage by the
             couple of a double-barrier method of contraception. Use of a single-barrier method
             alone or abstinence alone is not considered adequate.

         11. Subject is willing and able to comply with all protocol procedures, evaluations and
             rescue measures.

        Exclusion Criteria:

          1. Presence of a serious co-morbid medical condition, or a clinically significant
             laboratory finding(s) that, in the opinion of the Investigator, suggests the presence
             of an infectious, endocrine, and/or other inadequately treated systemic disorder.

          2. A known active bacterial, fungal, or viral infection. No subjects with an active
             SARS-CoV-2 infection (within 21 days of a positive test).

          3. Known positive human immunodeficiency virus (HIV)

          4. Known history of hepatitis B or C. Patients with a known history of hepatitis B or C
             will be eligible only if they have an undetectable viral load during screening.

          5. If female, subject is pregnant and/or breastfeeding.

          6. Subjects with active autoimmune disease or history of autoimmune disease that might
             recur and may affect vital organ function or require immune suppressive treatment
             including systemic corticosteroids, should be excluded. NOTE: Subjects having a
             condition requiring systemic treatment with either corticosteroids (> 10 mg daily
             prednisone equivalents) or other immunosuppressive medications within 14 days of study
             agent administration. Treatment with non-steroidal anti-inflammatory drugs (NSAIDs) is
             allowed.

          7. Prior adenoviral therapy for any indication except vaccination against infectious
             disease. If subject received a COVID-19 vaccination, cannot start treatment until 14
             days after completing the vaccination series. Recommend waiting at least 28 days from
             AdAPT-001 dose prior to receiving COVID-19 vaccination (end of 28 Day Follow Up visit
             in Part 1).

          8. Chemotherapy or immunotherapy within 14 days of study treatment. Hormonal therapy
             (including tamoxifen, aromatase inhibitors, and gonadotropin releasing hormone
             agonists) is allowed. Concurrent treatment with bisphosphonate and RANK ligand
             inhibitor is allowed.